|
End-of-day quote
Buenos Aires S.E.
12/08/2026
|
5-day change | 1st Jan Change | ||
| 62,850.00 ARS | -0.08% |
|
-0.91% | -10.91% |
| 06:44am | CSPC Innovation Pharmaceutical Gets $30 Million Initial Payment for Nucleic Acid Development Deal With AstraZeneca | MT |
| 08-12 | Octave slid after earnings report, OMXS30 index down 0.2% | FW |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- AZN Stock
- AZN Stock
- Consensus AstraZeneca PLC
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
